Interim results from a phase 1/2 study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN).

已取消 10 由行止发布于 2025/6/6 0:31:03

文献类型：期刊论文
补充材料：只需要正文
管理员驳回:Free Access, https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.4_suppl.121

American Society of Clinical Oncology (ASCO)

应助信息

2025-06-06

Book学术机器人

2025/6/6 0:31:03 未找到该文献，机器人已退出，请等待人工下载

2025/6/6 0:31:03 Book学术AI机器人收到请求，开始寻找文献

2025/6/6 0:31:03 已向机器人发送请求

2025-06-06

行止发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:其它数据库Durable response to combination radiotherapy and immunotherapy in EP-resistant lung large-cell neuroendocrine carcinoma with <i>B2M</i> and <i>STK11</i> mutations: a case report.